# Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients

> **NCT00507442** · PHASE1,PHASE2 · COMPLETED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 158 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** VELCADE (bortezomib)
- **DRUG:** dexamethasone
- **DRUG:** cyclophosphamide
- **DRUG:** Revlimid (lenalidomide)

## Key facts

- **NCT ID:** NCT00507442
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2010-10
- **Final completion:** 2010-11
- **Target enrollment:** 158 (ACTUAL)
- **Last updated:** 2013-07-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00507442

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00507442, "Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00507442. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*